Spasticity Management Drugs Market Global Report 2026

The spasticity management drugs market size has grown strongly in recent years. It will grow from $3.99 billion in 2025 to $4.26 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to rising incidence of neurological conditions such as stroke and cerebral palsy, limited effectiveness of conventional muscle relaxant treatments, expanding geriatric population experiencing mobility limitations, increasing awareness of rehabilitation medicine, and wider adoption of hospital-based neurology care services.

The spasticity management drugs market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The forecast period growth can be attributed to advancements in targeted neuro-modulatory drug development, increasing adoption of botulinum toxin-based therapies, rising demand for minimally invasive neurological treatments, integration of precision medicine in neurology care, and expansion of rehabilitation-focused healthcare infrastructure. Major trends include personalized neuro-rehabilitation pharmacological approaches, development of advanced botulinum toxin formulations for spasticity control, combination drug regimens for muscle relaxation, biomarker-guided neurological treatment strategies, and long-acting injectable therapies for spasticity management.

The increasing prevalence of neurological disorders is expected to drive the growth of the spasticity management drugs market going forward. Neurological disorders are medical conditions that impact the brain, spinal cord, and nervous system, resulting in symptoms such as muscle stiffness, involuntary spasms, impaired movement, and loss of motor coordination. The rising prevalence of neurological disorders is mainly driven by the aging global population, as higher life expectancy increases the likelihood of age-related degeneration of the brain and nervous system, thereby leading to greater demand for treatment and management. Spasticity management drugs assist in neurological disorders by reducing muscle stiffness, involuntary muscle spasms, and pain, thereby enhancing mobility, comfort, and overall motor function in patients. For instance, in March 2024, according to the Alzheimer’s Association, a US-based nonprofit health organization, around 6.9 million Americans aged 65 years and older were living with Alzheimer’s disease in 2024, compared to 6.7 million in 2023. Therefore, the increasing prevalence of neurological disorders is driving the growth of the spasticity management drugs market.

The expansion of healthcare infrastructure is expected to drive the growth of the spasticity management drugs market going forward. Healthcare infrastructure expansion refers to the development and growth of physical facilities, clinical services, and health systems that enhance the delivery of medical care to patients. The expansion of healthcare infrastructure is primarily driven by the increasing burden of neurological disorders such as multiple sclerosis, stroke, and cerebral palsy, which has pushed governments and health systems to invest in building and scaling specialized care facilities, including neurology clinics and rehabilitation centers, to address rising patient demand. As healthcare infrastructure expands, a larger number of patients gain access to specialized neurological care, enabling earlier diagnosis and continuous pharmacological treatment, which directly increases the adoption and utilization of drugs used to manage spasticity. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the expansion of healthcare infrastructure is driving the growth of the spasticity management drugs market.

Leading companies operating in the spasticity management drugs market are focusing on the development of advanced products such as intrathecal administration sterile solutions to improve targeted drug delivery and enhance spasticity symptom control. Intrathecal administration of sterile solutions is a specialized formulation of medications delivered directly into the spinal fluid to provide targeted and long-lasting relief from severe spasticity while reducing systemic side effects. For example, in March 2024, Nexus Pharmaceuticals, a US-based pharmaceutical manufacturing company, launched Baclofen Injection USP, a sterile intrathecal administration solution designed as a muscle relaxant and antispasmodic treatment. The product is used for patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other neurological conditions causing severe muscle spasms. The injection helps relieve flexor spasms, clonus, and associated pain while also improving sleep quality and supporting patients who are unable to tolerate oral baclofen formulations.

Major companies operating in the spasticity management drugs market are AbbVie Inc., Novartis AG, Ipsen Pharma, Merz Therapeutics GmbH, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals Inc., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Emcure Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Pfizer Inc.

North America was the dominant region in the spasticity management drugs market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in spasticity management drugs report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spasticity management drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The spasticity management drugs market consists of sales of muscle relaxants, antispastic medications, and supportive therapeutic drugs. values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators0 of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The spasticity management drugs market research report is one of a series of new reports that provides spasticity management drugs market statistics, including spasticity management drugs industry global market size, regional shares, competitors with a spasticity management drugs market share, detailed spasticity management drugs market segments, market trends and opportunities, and any further data you may need to thrive in the spasticity management drugs industry. This spasticity management drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.